The US Food and Drug Administration has approved the first drug for Alzheimer’s disease in nearly two decades. But not everyone is welcoming the decision.
The US Food and Drug Administration has approved the first drug for Alzheimer’s disease in nearly two decades.
But not everyone is welcoming the decision.
While some clinicians, patients and their families think the drug provides hope to those living with the disease, others are worried there’s not enough evidence to prove it benefits patients, and that putting it on the market will only stall the development of other drugs and potentially waste enormous amounts of money.
Among those concerned are scientists who advise the FDA.
And here in Australia, authorities are considering whether to also give Aducanumab the green light.
Originally published at Abc news